Zoledronic Acid Results in Better Health-related Quality of Life Following Hip Fracture: the HORIZON-Recurrent Fracture Trial

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2011 Jan 21

PMID 21249332

Citations 16

Authors

J D Adachi

K W Lyles

C S Colon-Emeric

S Boonen

C F Pieper

C Mautalen

L Hyldstrup

C Recknor

L Nordsletten

K A Moore

C Bucci-Rechtweg

G Su

E F Eriksen

J S Magaziner

Affiliations

Soon will be listed here.

Abstract

Unlabelled: This study evaluated the benefits of ZOL versus placebo on health-related quality of life (HRQoL) among patients from HORIZON-RFT. At month 24 and end of the study visit, ZOL significantly improved patients' overall health state compared to placebo as assessed by the EQ-5D VAS.

Introduction: To evaluate the benefits of zoledronic acid (ZOL) versus placebo on health-related quality of life (HRQoL) among patients from The Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Recurrent Fracture Trial (HORIZON-RFT).

Methods: In this randomized, double-blind, placebo-controlled trial, 2,127 patients were randomized to receive annual infusion of ZOL 5 mg (n = 1,065) or placebo (n = 1,062) within 90 days after surgical repair of low-trauma hip fracture. HRQoL was measured using EQ-5D Visual Analogue Scale (VAS) and utility scores (EuroQol instrument) at months 6, 12, 24, 36, and end of the study visit. Analysis of covariance model included baseline EQ-5D value, region, and treatment as explanatory variables.

Results: At baseline, patients (mean age 75 years; 24% men and 76% women) were well matched between treatment groups with mean EQ-5D VAS of 65.82 in ZOL and 65.70 in placebo group. At the end of the study, mean change from baseline in EQ-5D VAS was greater for ZOL vs. placebo in all patients (7.67 ± 0.56 vs. 5.42 ± 0.56), and in subgroups of patients experiencing clinical vertebral fractures (8.86 ± 4.91 vs. -1.69 ± 3.42), non-vertebral fractures (5.03 ± 2.48 vs. -1.07 ± 2.16), and clinical fractures (5.19 ± 2.25 vs. -0.72 ± 1.82) with treatment difference significantly in favor of ZOL. EQ-5D utility scores were comparable for ZOL and placebo groups, but more patients on placebo consistently had extreme difficulty in mobility (1.74% for ZOL vs. 2.13% for placebo; p = 0.6238), self-care (4.92% vs. 6.69%; p = 0.1013), and usual activities (10.28% vs. 12.91%; p = 0.0775).

Conclusion: ZOL significantly improves HRQoL in patients with low-trauma hip fracture.

Citing Articles

Post-surgery interventions for hip fracture: a systematic review of randomized controlled trials.

Phang J, Lim Z, Yee W, Tan C, Kwan Y, Low L BMC Musculoskelet Disord. 2023; 24(1):417.

PMID: 37231406 PMC: 10210378. DOI: 10.1186/s12891-023-06512-9.

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R Front Endocrinol (Lausanne). 2023; 14:1137671.

PMID: 37143730 PMC: 10151776. DOI: 10.3389/fendo.2023.1137671.

Endogenous repair theory enriches construction strategies for orthopaedic biomaterials: a narrative review.

Peng Y, Li J, Lin H, Tian S, Liu S, Pu F Biomater Transl. 2022; 2(4):343-360.

PMID: 35837417 PMC: 9255795. DOI: 10.12336/biomatertransl.2021.04.008.

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation.

He Q, Yang J, Chen D, Li Y, Gong D, Ge H Front Pharmacol. 2022; 13:899776.

PMID: 35721216 PMC: 9204068. DOI: 10.3389/fphar.2022.899776.

Epidemiology and reporting of osteoporotic vertebral fractures in patients with long-term hospital records based on routine clinical CT imaging.

Loffler M, Kallweit M, Niederreiter E, Baum T, Makowski M, Zimmer C Osteoporos Int. 2021; 33(3):685-694.

PMID: 34648040 PMC: 8844161. DOI: 10.1007/s00198-021-06169-x.

References

Papaioannou A, Kennedy C, Ioannidis G, Sawka A, Hopman W, Pickard L . The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2008; 20(5):703-14. PMC: 5101052. DOI: 10.1007/s00198-008-0743-7. View

Cummings S, Melton L . Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359(9319):1761-7. DOI: 10.1016/S0140-6736(02)08657-9. View

Sawka A, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Papadimitropoulos E . Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2005; 16(12):1836-40. DOI: 10.1007/s00198-005-1949-6. View

Tosteson A, Gabriel S, Grove M, Moncur M, Kneeland T, Melton 3rd L . Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2002; 12(12):1042-9. DOI: 10.1007/s001980170015. View

Adachi J, Ioannidis G, Pickard L, Berger C, Prior J, Joseph L . The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int. 2003; 14(11):895-904. DOI: 10.1007/s00198-003-1483-3. View

Oleksik A, Ewing S, Shen W, van Schoor N, Lips P . Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int. 2004; 16(8):861-70. DOI: 10.1007/s00198-004-1774-3. View

Ioannidis G, Papaioannou A, Hopman W, Akhtar-Danesh N, Anastassiades T, Pickard L . Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009; 181(5):265-71. PMC: 2734204. DOI: 10.1503/cmaj.081720. View

Colon-Emeric C, Caminis J, Suh T, Pieper C, Janning C, Magaziner J . The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin. 2004; 20(6):903-10. DOI: 10.1185/030079904125003683. View

Oleksik A, Lips P, Dawson A, Minshall M, Shen W, Cooper C . Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000; 15(7):1384-92. DOI: 10.1359/jbmr.2000.15.7.1384. View

10.

Silverman S, Minshall M, Shen W, Harper K, Xie S . The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum. 2001; 44(11):2611-9. DOI: 10.1002/1529-0131(200111)44:11<2611::aid-art441>3.0.co;2-n. View

11.

Brazier J, Walters S, Nicholl J, Kohler B . Using the SF-36 and Euroqol on an elderly population. Qual Life Res. 1996; 5(2):195-204. DOI: 10.1007/BF00434741. View

12.

Dhillon V, Hurst N, Hannan J, Nuki G . Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int. 2005; 16(5):483-9. DOI: 10.1007/s00198-004-1705-3. View

13.

Rosen C, Brown S . Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003; 348(15):1503-4. DOI: 10.1056/NEJM200304103481521. View

14.

Papaioannou A, Kennedy C, Ioannidis G, Brown J, Pathak A, Hanley D . Determinants of health-related quality of life in women with vertebral fractures. Osteoporos Int. 2005; 17(3):355-63. DOI: 10.1007/s00198-005-2020-3. View

15.

Silverman S, Piziak V, Chen P, Misurski D, Wagman R . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol. 2005; 32(12):2405-9. View

16.

Brooks R . EuroQol: the current state of play. Health Policy. 1996; 37(1):53-72. DOI: 10.1016/0168-8510(96)00822-6. View

17.

Meunier P, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P . Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20(10):1663-73. PMC: 2744775. DOI: 10.1007/s00198-008-0825-6. View

18.

Marquis P, Cialdella P, de la Loge C . Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res. 2002; 10(6):555-66. DOI: 10.1023/a:1013041206433. View

19.

Lips P, Jameson K, Bianchi M, Goemaere S, Boonen S, Reeve J . Validation of the IOF quality of life questionnaire for patients with wrist fracture. Osteoporos Int. 2009; 21(1):61-70. PMC: 2788146. DOI: 10.1007/s00198-009-0946-6. View

20.

Silverman S, Cranney A . Quality of life measurement in osteoporosis. J Rheumatol. 1997; 24(6):1218-21. View